BioLineRx (BLRX) Receivables - Other (2021 - 2025)

BioLineRx has reported Receivables - Other over the past 5 years, most recently at $410000.0 for Q4 2025.

  • Quarterly results put Receivables - Other at $410000.0 for Q4 2025, down 72.26% from a year ago — trailing twelve months through Dec 2025 was $410000.0 (down 72.26% YoY), and the annual figure for FY2025 was $410000.0, down 72.26%.
  • Receivables - Other for Q4 2025 was $410000.0 at BioLineRx, down from $1.5 million in the prior quarter.
  • Over the last five years, Receivables - Other for BLRX hit a ceiling of $1.5 million in Q4 2024 and a floor of $142000.0 in Q4 2021.
  • Median Receivables - Other over the past 5 years was $721000.0 (2022), compared with a mean of $716200.0.
  • Biggest five-year swings in Receivables - Other: surged 407.75% in 2022 and later plummeted 72.26% in 2025.
  • BioLineRx's Receivables - Other stood at $142000.0 in 2021, then surged by 407.75% to $721000.0 in 2022, then grew by 15.12% to $830000.0 in 2023, then soared by 78.07% to $1.5 million in 2024, then plummeted by 72.26% to $410000.0 in 2025.
  • The last three reported values for Receivables - Other were $410000.0 (Q4 2025), $1.5 million (Q4 2024), and $830000.0 (Q4 2023) per Business Quant data.